The Peptide Conversation: What Your Patients Are Already Googling

A patient mentions BPC-157. The reflexive answer is that there is no good human evidence for it, which is true. It is also, on its own, the least useful thing you can say, because the patient has already read a hundred pages arguing otherwise, has probably heard a podcast in which someone credible-sounding described it working, and has a vial in their refrigerator.

Being right is not the same as being useful here. The clinical objective is not to win the exchange. It is to find out what they are taking, from where, at what dose, and to remain the person they tell when something goes wrong.

What they are actually searching

The shape of the demand is worth understanding, because it is not what most clinicians assume.

At the head of the curve are approved drugs. Semaglutide and tirzepatide generate search volume that dwarfs everything else, and most of those searches come from patients who either have a prescription or want one. That part is conventional medicine, however it is being marketed.

The long tail is different. BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, PT-141, semax and sermorelin sustain substantial and growing interest, and none of them is an approved medicine for these uses. The clearest illustration is retatrutide, an investigational triple agonist still in phase 3 trials, which has become one of the most-searched peptides of 2026 despite the fact that it cannot legally be prescribed, compounded or purchased anywhere in the world. [1]

Patients are searching for, and in some cases obtaining, a molecule that exists only inside clinical trials.

That single fact tells you most of what you need to know about the market your patients are navigating. The gap between what is discussed and what is legally available is not a small one, and it is being filled by vendors.

Why they do not tell you

Non-disclosure of non-prescribed treatment is one of the better-studied phenomena in this area, and the findings are consistent enough to plan around.

A meta-analysis of 86 studies found that roughly a third of patients using complementary medicine did not disclose it to their medical provider. [2]

A separate analysis of national survey data put non-disclosure of the most-used modality higher still, at around 42%. [3]

The reasons matter more than the rate. Across studies, the two most frequently cited are fear of the provider's disapproval and the provider simply never asking. Patients also report believing the clinician would have no relevant knowledge, and that the treatment was safe and therefore not worth mentioning.

Read that list from a clinical design perspective and it is close to a set of instructions. Non-disclosure is not primarily a patient failing. It is a predictable response to a consultation that does not ask, delivered by someone the patient expects to be dismissive, about a subject they suspect the clinician knows little about. Each of those is modifiable.

What is actually in the vial

Here is where the conversation becomes concrete, and where the physician has something to offer that the internet does not.

An analysis of 6,441 samples across fourteen compounds — including BPC-157, CJC-1295, ipamorelin, retatrutide, semaglutide, sermorelin, TB-500 and tirzepatide — drawn from an independent testing dataset of directly marketed research-grade peptides applied two quality frameworks. Depending on which standard was used, between 41.6% and 71.1% of samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in around 15%. [4]

This finding does the clinical work that arguing about mechanism cannot. You can concede the underlying biology entirely — grant that BPC-157 has a large preclinical literature, that the receptor pharmacology is plausible, that the patient's trainer may sincerely believe it helped — and the sourcing problem remains untouched. A compound cannot be evaluated if the vial does not reliably contain it.

The common contaminants are worth being able to name, because specificity is persuasive where generality is not: truncated synthesis fragments with unknown activity, residual solvents and counterions, bacterial endotoxin, and quantities that differ substantially from the label. A patient who has been reassured by a certificate of analysis supplied by the seller should understand that this is a document produced by the party with the strongest interest in its contents.

Running the conversation

What follows is a sequence rather than a script, and it takes very little additional consultation time.

Ask, routinely and without prompting. Add peptides explicitly to the medication history alongside supplements and over-the-counter products. The single most common reason for non-disclosure is that nobody asked, and the question normalises the answer. Asking about "anything you inject or take that wasn't prescribed here" catches more than asking about peptides by name.

Separate the three questions. Patients experience their question as one thing. It is almost always three: is the underlying biology plausible, is this particular product what it claims to be, and is this legal and monitorable? These have different answers, and the answers frequently diverge. A compound can have interesting biology, a terrible supply chain and no legal pathway simultaneously, and saying so is more credible than a blanket dismissal.

Establish the specifics. What compound, what dose, what route, from which vendor, for how long, and what else alongside it. Stacking is common and largely undocumented. If they are also on an approved GLP-1, that interaction matters and belongs in the record.

Say what you do not know. The evidence base for most of these compounds is preclinical. Stating that plainly, and distinguishing it from "this does not work," preserves credibility for the occasions when you need to be firm about something.

Document and follow up. Record what was disclosed and what was advised. Set a review point rather than closing the topic. A patient who expects to be asked again is more likely to report a problem early.

What not to do

Do not feign familiarity with a compound you have not heard of. Patients researching this material are often better read on the specific molecule than you are, and being caught bluffing costs you the rest of the consultation.

Do not moralise. Disapproval is among the most commonly cited reasons patients withhold information, and it converts a manageable disclosure into a hidden one.

Do not treat the question as a proxy for foolishness. Many of these patients are engaged, motivated and pursuing goals — recovery, function, healthspan — that are entirely reasonable. The reasoning that led them to an unregulated vendor usually started somewhere legitimate.

And do not promise to look into something and then never return to it. That is the most reliable way to establish that the internet is a more responsive source of information than you are.

The realistic objective

You are unlikely to talk most patients out of an interest in peptides, and framing the encounter as an attempt to do so almost guarantees losing visibility of what they are actually taking.

What you can achieve is more modest and more valuable: accurate disclosure, a documented record, a patient who understands the difference between an approved drug and a substance bought under a research-use label, and an open channel if something goes wrong. That is a good outcome. It is also, given how this market is currently structured, roughly the best one available.

For the underlying pharmacology, see What are peptides? A clinician's primer on peptide vs protein signalling. For how this gap in training arose, see Why peptides weren't in your medical training.